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Abstract
Background: The modelling framework is proposed to study protection properties of
antibodies to neutralize the effects of the plant toxin (ricin). The present study extends
our previous work by including (i) the model of intracellular transport of toxin to the
Endoplasmic Reticulum and (ii) the model of the internalised antibodies (when
antibody is delivered directly into the cytosol).
Method: Simulation of the receptor-toxin-antibody interaction is implemented by
solving the systems of PDEs (advection-diffusion models) or ODEs (rate models) for the
underlying transport coupled with mass-action kinetics.
Results: As the main application of the enhanced framework we present a
comparative study of two kinds (external and internalised) of antibodies. This
comparison is based on calculation of the non-dimensional protection factor using the
same set of parameters (geometry, binding constants, initial concentrations of species,
and total initial amount of the antibody).
Conclusion: This research will provide a framework for consistent evaluation and
comparison of different types of antibodies for toxicological applications.
Keywords: Toxin, Antibody, Cell receptor, Intracellular transport
Background
The plant toxin ricin made from the seeds of the castor oil plant is highly toxic to mam-
malian cells. It is one of the deadliest toxins known and is classified as a potential bioterror
agent for which no treatment is available. Some promising results have been shown
recently in the immunotherapeutic approach, i.e. application of antibodies to neutralise
the effects of ricin [1-4].With the recent progress in bio-engineering, antibodies with high
affinity have been generated. The development and production of new antibodies is still
an expensive process that usually includes extensive experimental studies with continu-
ous experimental refinement of antibodies properties. Evidently, that such a retrospective
evaluation of different antibodies aiming at selection of the best candidate may become
very time and resource consuming.
In order to reduce this experimental burden a simple (but scientifically consistent)mod-
elling framework has been recently proposed [5-9]. This framework enables extensive
theoretical optimization studies to increase the protective potential of antibodies before
proceeding with targeted experimental studies.
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The mechanism of ricin intracellular transport involves a number of steps each with
its complex phenomenology which are well-documented (see [1-4] and Refs. therein).
Ricin consists of an A (RTA) and B (RTB) chain linked by a disulphide bond. RTB binds
to a cell surface receptor triggering uptake and retrograde transport to the Endoplasmic
Reticulum (ER). In the ER, the RTA and RTB chains are separated and the RTA is translo-
cated across the ER membrane into the cytosol. Subsequently RTA reaches ribosome and
damages the protein production machinery of the cell resulting in the cell death. In this
context, the toxin concentration in the cytoplasm near ER becomes the critical quantity to
estimate the toxicological impact of ricin on the cell and evaluate the protective potential
of the antibody. Thiswas amotivation to introduce a consistent quantitative characteristic
for antibody comparison (see below).
For the sake of parametrisation simplicity the coarse-grained modeling framework pro-
posed in [5-9] seemingly ignores these fine details of toxin binding and internalisation.
In fact, it is aimed at capturing the complexity of these processes by means of a small
number of ‘aggregated’ rate constants that can be (or have been) evaluated experimen-
tally or numerically. Such kind of models becomes a conventional tool in pharmacological
modeling (for example, see [10] and Refs. therein). From the chemical point of view the
framework is similar to one well-established in electrochemistry where it is used for esti-
mation of uptake rates of the heavy metal ions from the environment, see [11-13]. A
practical application of the proposed models involves a numerical (or sometimes ana-
lytical) solution of a nonlinear system of PDEs (diffusion kinetics) for a given set (or
range) of antibody parameters (i.e. binding rates, concentration) to infer the effect of these
parameters on the protective potential of the antibody.
In the present paper we extend our previous work [5-9] by refining models for intra-
cellular transport and chemical interaction of species. Motivated by experimental studies
available in the literature [1-4] and possible toxicological applications we consider two
scenarios of antibody delivery. In the first scenario (below refer to as Scenario I) the anti-
body is placed inside the cell between the ER and cell membrane. The toxin initially is
delivered outside the cell (in the extracellular domain). Then it moves toward the cell
and interacts with receptors on the cell membrane. Some of toxin penetrates into the
cell, where it further moves toward the ER (see Figure 1a) and eventually interacts with
antibody.
In the second scenario (Scenario II) the antibody is delivered outside the cell where it
initially interacts with the toxin partially neutralising it. The free toxin moves toward the
cell membrane where it interacts withmembrane receptors. Some of toxin penetrates into
the cell where it is subsequently transported toward ER (see Figure 1b).
To model biologically complex phenomenology of species transport in cell we employ
the following physical mechanisms: (i) diffusion (for species in extracellular space), (ii)
diffusion and advection (direction transport via microtubule network) for toxin and
only diffusion for antibody and toxin-antibody complex inside the cell, (iii) mass-action
kinetics (to form complexes and describe binding processes).
Although all parts of the model have been implemented with the standard numerical
algorithm (an implicit finite-difference scheme [14]), an interpretation of its output and
parameters tuning requires some domain knowledge (solution of nonlinear systems of
PDEs). In order to reduce dimension of the parameter space of the models and ameliorate
their operational application we also considered so-called simplified (or reduced) models
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Figure 1 The schematic diagram of receptor-toxin-antibody system: (a) - Scenario I and
(b) - Scenario II. – toxin,♦ – antibody, conglutinated  and ♦ in circle – toxin-antibody complex, external
sphere – cell membrane, internal sphere – ER envelope.
for each scenario. The simplified (sometimes called compartment) models are based on
the ‘well-mixed’ assumption which states that all species have uniform concentration
across the modeling domain. This assumption eliminates the a necessity to calculate the
gradient driven fluxes in the models (i.e. diffusion) leading to a significant simplification
(translation from PDEs to ODEs). By comparing outputs of complete and reduced mod-
els we can infer and defensively comment on the trade-off between simplicity and fidelity
in modeling approach to an evaluation of each scenario.
As the main application of this framework we present a comparative study of external
(conventional) and internalised antibodies. More specifically, for the same set of parame-
ters (geometry, binding constants, initial concentration or initial amount of antibody) we
calculate the non-dimensional parameter
δ(t) = uT (t, ρn)|A∈iuT (t, ρn)|A∈e
, (1)
which is a ratio of reductions of toxin concentration in the cytoplasm due to introduc-
tion of two kinds of antibodies. Here uT (t, ρn)|A∈i , uT (t, ρn)|A∈e is the concentration
of internalized toxin near ER for the case of internalized (i) and external antibody (e). The
time evolution of this aggregated parameter δ(t) enables a consistent comparison of two
scenarios of antibody treatment (i.e. either delivered extracellularly or into the cytosol).
For instance, the condition δ < 1 indicates that internalised antibody performs better
than conventional antibody, while at δ > 1 the conventional antibody outperforms. This
comparison is the main outcome of our study.
The paper is organised as follows. In Section ‘The models’ we introduce models for
toxin-antibody interaction outside and inside the cell. Results are discussed in Section
‘Numerical results’. Conclusions and summarising remarks are presented in Section
‘Conclusions’.
Notation
We use the notation of papers [5-7]:
T and A – the toxin and antibody;
C = TA – the toxin-antibody complex (nontoxic);
Skakauskas et al. Theoretical Biology andMedical Modelling 2014, 11:11 Page 4 of 16
http://www.tbiomed.com/content/11/1/11
ρ – the distance to the origin;
Sm = {ρ : ρ = ρm} – the surface of the membrane of a spherical cell;
Se = {ρ : ρ = ρe}, ρe > ρm – the surface of the external sphere (external surface of
e);
e = {ρ : ρ ∈ (ρm, ρe)} – the extracellular domain;
Sn = {ρ : ρ = ρn}, ρn < ρm – the surface of the spherical envelope of the domain
occupied by ER;
i = {ρ : ρ ∈ (ρn, ρm)} – the intracellular domain;
r0 – the concentration of receptors confined to the cell membrane;
θ – the fraction of the toxin-bound receptors;
r0θ – the concentration of the toxin-bound receptors;
r0(1 − θ) – the concentration of the free receptors;
uA and uC – the concentrations of the antibody and toxin-antibody complex,
respectively, in the domains i or e;
uT – the toxin concentration in e ∪ i;
u0T , u0eA , u0iA – the initial concentrations of the toxin and antibody in e and i,
respectively;
κT , κA, κC – the diffusivity of the toxin, antibody, and toxin-antibody complex,
respectively;
k1, k−1 – the forward and reverse constants of the toxin-antibody reaction rate;
k2 and k−2 – the forward and reverse binding rate constants of the toxin and receptor
confined on the membrane;
k – the toxin internalization rate constant from e across the membrane into the cell;
γ – the toxin absorption rate constant describing toxin influx into ER;
v(ρ), v > 0 – the toxin advective velocity;
∂t = ∂/∂t, 	 = ρ−2 ∂∂ρ (ρ2 ∂∂ρ ) – the Laplace operator.
Themodels
As mentioned above we study two scenarios of antibody delivery. In Scenario I the
antibody is delivered inside the cell, i.e. in domaini (space between the ER and cell mem-
brane) while in Scenario II it is delivered outside the cell (space between cell membrane
and external boundary of the extracellular domain, e). In the Scenario I toxin being ini-
tially in e (extracellular domain) moves toward the cell and interacts with receptors on
the cell membrane. Subsequently some of toxin penetrates into the intracellular domain,
i, where it moves toward ER and interacts with antibody. Toxin competitively reacts
with antibody in the extracellular domain (Scenario II) or inside the cell (Scenario I). This
‘blocking’ reaction results in a reduced toxin concentration on the ER envelope and is the
main bio-chemical mechanism of toxin neutralization by antibody.
In order to extend our results from a single cell model to many-cell systems we impose
the no-toxin flux boundary condition on the external surface Se of the extracellular
domain e (to mimic periodicity of the infinite system). This also accounts for conserva-
tion of species in the system and enables consistent simulation of depletion effects (see
[13] for details).
It is well-known that binding of toxin to antibody and toxin to receptors are reversible
reactions, that can be described by the equations of mass-action kinetics (see [5-10] and
Refs. therein). In the context of study of processes in the Scenario I these equations
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have been modified to include toxin directional transport and diffusion of all species
in the intracellular domain (by adding appropriate advection and diffusion terms, e.g.
see [15,16]). To describe extracellular transport and toxin binding by cell receptors we
model the cell as a partially absorbing sphere with distributed binding sites that follow
the Langmuir adsorption model. In the intracellular domain of the Scenario I the toxin
transport is modelled by the advection-diffusion equation in which an advective velocity
(drift) is introduced to account for directional transport via microtubule network. For the
transport of the antibody and antibody-toxin complexes we still use the pure diffusion
mechanism. We also assume that antibody and toxin-antibody complexes do not inter-
nalize and never cross the cell membrane or the ER envelope (internal concentric sphere).
The schematic diagram of receptor-toxin-antibody system is presented in Figure 1.
Since the process of receptor binding is very rapid (seconds) and toxin internalization
is relatively slow (hours) we can effectively decoupled the model for extracellular and
intracellular domains and solve them sequentially. The relative values of time scales for
receptor binding and toxin internalization have also been validated retrospectively and
found to be consistent with the initial assumption of domains decoupling (see below).
The Advection-DiffusionModel used to evaluate Scenario I is an extension of the mod-
els previously published [4-9]. The following new processes have been included in our
simulations: (i) the intracellular traffic that captures the diffusion of all species and the
main features of the toxin microtubule transport, (ii) chemical interaction of all species
inside the cell (see [15] and Refs. therein), and (iii) process of the toxin transport to ER.
In order to model toxin transport towards the ER a special boundary condition was
introduced on the ER envelope. The radius of that spherical envelope was about the size
of the domain occupied by the ER. It is assumed that the mixed (or radiation) bound-
ary condition for species concentrations can capture (at least phenomenologically) the
complexity of toxin kinetics inside the ER [17].
Now we can formulate the equations for the Advection-Diffusion Model (refer to as the
ADM1 model). In extracellular space e we have the following set of equations:⎧⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎩
∂tuT = κT	uT , ρ ∈ (ρm, ρe), t > 0,
∂ρuT = 0, ρ = ρe, t > 0,
∂ρuT = r0
κT
(k2(1 − θ)uT − k−2θ), ρ = ρm, t > 0,
uT |t=0 = u0T , ρ ∈ (ρm, ρe),
(2)
{
∂tθ = k2(1 − θ)uT − k−2θ − kθ , ρ = ρm, t > 0,
θ |t=0 = 0, ρ = ρm.
(3)
Function θ determined from solution by these equations is used as the boundary
condition in the equations in intracellular domain i:⎧⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎩
∂tuT = −k1uTuA + k−1uC + κT	uT + ∂ρ(vuT ) + 2vuT/ρ,
ρ ∈ (ρn, ρm), t > 0,
κT∂ρuT = r0kθ − vuT , ρ = ρm, t > 0,
κT∂ρuT = (γ − v)uT , ρ = ρn, t > 0,
uT |t=0 = 0, ρ ∈ (ρn, ρm),
(4)




∂tuA = −k1uTuA + k−1uC + κA	uA, ρ ∈ (ρn, ρm), t > 0,
∂ρuA = 0, ρ = ρm, t > 0,
∂ρuA = 0, ρ = ρn, t > 0,




∂tuC = k1uTuA − k−1uC + κC	uC , ρ ∈ (ρn, ρm), t > 0,
∂ρuC = 0, ρ = ρm, t > 0,
∂ρuC = 0, ρ = ρn, t > 0,
uC|t=0 = 0, ρ ∈ (ρn, ρm).
(6)
The set of Eqs. (2)–(6) composes the ADM1model. The main parameter of interest for
the Scenario I is the antibody protection factor (a relative reduction of the internalized
toxin due to application of antibody) defined by the expression





By definition, 0 ≤ μ1(t) ≤ 1 with the lower values of μ1(t) corresponding to the more
profound therapeutic effect of antibody treatment.
To simplify the ADM1model we employ the ‘well-mixed’ assumption [5]. This assump-
tion implies that all species (toxin, antibody, and toxin-antibody complex) are uniformly
distributed in the calculation domain for all time, so there is no spatial gradients of con-
centrations. Under this condition all flux terms disappear from the equations of ADM1.
The process of toxin internalization (i.e. flux of toxin through the cell surface Sm and ER
envelope Sn) can be modelled as an appropriate rate of toxin removal from e and i,
respectively.
It is worth emphasizing that a reduction to the ‘well-mixed’ (or compartment) mod-
els requires fulfilment of some condition that can be formulated in terms of a smallness
of the ratio 
 = τκ/τR, where τκ and τR is a diffusion and reaction time scale in the
system, respectively (diffusion can quickly restore any spatial inhomogeneity of species
distribution maintaining uniform concentration). In the simplest case τκ ∼ a2/κ and
τR ∼ 1/k, where a is a characteristic length scale, κ is a scale of diffusivity and k is the scale
of reaction rate. This is condition for what is called diffusion- or reaction–dominated
regimes in diffusion kinetics [18]. Indeed, this condition does not always hold and we do
not assume that it satisfies automatically in the context of our study. Since our models
are characterized by a number of spatial scales (extracellular and intracellular domains,
ER envelope), hierarchy of reaction rates and diffusion coefficients, it is very difficult
(or even impossible) to formulate and validate any general criteria for the feasibility of
the well-mixed assumption. For this reason we take a heuristic approach in which this
assumption is validated retrospectively by comparing the output of the models, viz. the
full (advection-diffusion) and reduced (compartment) models.
Under the well-mixed assumption the ADM1 model reduces to two ODEs.⎧⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎩
u˙T = −k3r0(k2(1 − θ)uT − k−2θ), t > 0,
uT |t=0 = u0T ,
θ˙ = k2(1 − θ)uT − k−2θ − kθ , t > 0,
θ |t=0 = 0,
(8)
Skakauskas et al. Theoretical Biology andMedical Modelling 2014, 11:11 Page 7 of 16
http://www.tbiomed.com/content/11/1/11
for extracellular domain e and three ODEs for inracelluar domain:⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
u˙T = −k1uTuA + k−1uC + kk4r0θ − k5γuT , t > 0,
uT |t=0 = 0,
u˙A = −k1uTuA + k−1uC , t > 0,
uA|t=0 = u0iA ,
u˙C = k1uTuA − k−1uC , t > 0,
uC|t=0 = 0,
(9)
with k3 = 3ρ2m/(ρ3e − ρ3m), k4 = 3ρ2m/(ρ3m − ρ3n), k5 = 3ρ2n/(ρ3m − ρ3n).
We call systems (8), (9) as the Well-Mixed Model 1 (WM1).
Analogously we formulate two models used to evaluate antibody protection properties
in Scenario II. For the extracellular domain e we employ the Diffusion Model proposed
in [5-7]:⎧⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎩
∂tuT = −k1uTuA + k−1uC + κT	uT , ρ ∈ (ρm, ρe), t > 0,
∂ρuT = 0, ρ = ρe, t > 0,
κT∂ρuT = r0{k2(1 − θ)uT − k−2θ}, ρ = ρm, t > 0,




∂tuA = −k1uTuA + k−1uC + κA	uA, ρ ∈ (ρm, ρe), t > 0,
∂ρuA = 0, ρ = ρe, t > 0,
∂ρuA = 0, ρ = ρm, t > 0,




∂tuC = k1uTuA − k−1uC + κC	uC , ρ ∈ (ρm, ρe), t > 0,
∂ρuC = 0, ρ = ρe, t > 0,
∂ρuC = 0, ρ = ρm, t > 0,
uC|t=0 = 0, ρ ∈ (ρm, ρe),
(12)
{
∂tθ = k2(1 − θ)uT − k−2θ − kθ , ρ = ρm, t > 0,
θ |t=0 = 0, ρ = ρm,
(13)
with toxin concentration in i being described by the Advection-Diffusion equation⎧⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎩
∂tuT = κT	uT + ∂ρ(vuT ) + 2vuT/ρ, ρ ∈ (ρn, ρm), t > 0,
κT∂ρuT = r0kθ − vuT , ρ = ρm, t > 0,
κT∂ρuT = (γ − v)uT , ρ = ρn, t > 0,
uT |t=0 = 0, ρ ∈ (ρn, ρm).
(14)
We refer to systems (10), (13) as the Advection-Diffusion Model 2 (ADM2). The main
parameter of interest evaluated with this model is the antibody protection factor
μ2(t) = uT (t, ρn;u
0
A)|A∈e
uT (t, ρn; 0)
. (15)
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Similarly to the Scenario I we can apply the well-mixed assumption to simplify this
model and reduce it to a set of ODEs⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
u˙T = −k1uTuA + k−1uC − k3r0(k2(1 − θ)uT − k−2θ), t > 0,
uT |t=0 = u0T ,
u˙A = −k1uTuA + k−1uC , t > 0,
uA|t=0 = u0eA ,
u˙C = k1uTuA − k−1uC , t > 0,
uC|t=0 = 0,
θ˙ = k2(1 − θ)uT − k−2θ − kθ , t > 0,
θ |t=0 = 0
(16)
in e and{
u˙T = kk4r0θ − γ k5uT , t > 0,
uT |t=0 = 0
(17)
in i. We call system (16) and (17) as the Well-Mixed Model 2 (WM2).
To compare the antibody protection capability in both scenarios (i.e. to infer which
scenario of antibody delivery is more beneficial for a particular type of antibody) we use
function δ(t) defined in Eq. (1) in which uT (t, ρn)|A∈i and uT (t, ρn)|A∈e are the toxin
concentrations near ER determined for the Scenario I and II, respectively. It is evident
that the following identity holds, δ(t) = μ1(t)/μ2(t).
It is convenient to translate Eqs. (1)–(17) to the non-dimensional form by using scales
of τ∗ (time), l (length), and u∗ (concentration). By substituting new variables, ρ = lρ¯,
t = τ∗ t¯, r0 = lu∗r¯0, uT = u∗u¯T , uA = u∗u¯A, uC = u∗u¯C , u0T = u∗u¯0T , u0A = u∗u¯0A,
k¯1 = τ∗u∗k1, k¯2 = τ∗u∗k2, k¯−1 = τ∗k−1, k¯−2 = τ∗k−2, k¯ = τ∗k, κ¯T = τ∗κT l−2, γ = lτ−1∗ γ¯ ,
v = lτ−1∗ v¯, κ¯A = τ∗κAl−2, κ¯C = τ∗κCl−2, k¯3 = lk3, k¯4 = lk4, k¯5 = lk5, into (1)–(17) we can
deduce the same systems, but now in non-dimensional form. Therefore, for simplicity in
what follows, we treat system (1)–(17) as non-dimensional.
Numerical results
We treated Eqs. (2)–(6), (8), (9), (10)–(14), and (16), (17) numerically for t > 0 in spher-
ically symmetric domains ρ ∈ (ρm, ρe) and ρ ∈ (ρn, ρm), respectively. We solve PDEs,
Eqs. (2)–(6) and Eqs. (10)–(14), by an implicit finite-difference scheme [14]. To solve
ODEs, Eqs. (8), (9) and Eqs. (16), (17), we apply the Runge–Kutta scheme.
Our selection of the values of parameters for the models (2)–(6), (8), (9), (10)–(14),
and (16), (17) was motivated by the values available in the literature [2,5,19-21] with an
extended range to allow exploration and illustration of the various transport regimes that
are possible inside the cell. The following values were used in simulations [18]: u∗ =
6.02 · 1013 cm−3, τ∗ = 1 s, r0 = 1.6 · 104/Sm, where 1.6 · 104 is the total number of
receptors of the cell, l = 10−2 cm, Sm = 4πρ2m = 4π · 10−6 cm2, r¯0 = 2.115 · 10−3. Values
of the dimensionless parameters were the following: ρn = 0.02, k = 3.3 · 10−5, k1 =
1.3 · 10−2, k−1 = 1.4 · 10−4, k2 = 1.25 · 10−2, k−2 = 5.2 · 10−2, κA = 10−2, κC =
10−2, u0iT = 0, r0 = 0.21 · 10−2, ρm = 0.1, ρe = 0.18. Values of κT and γ are given in the
legends of plots. The standard value of v is 0.001. Otherwise it is given in legends of plots.
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We expect that the chosen values of the parameters were representative enough to illus-
trate a rich variety of possible scenarios of the evolution of the Receptor-Toxin-Antibody
system and provide a reasonable estimate of time scales of the associated dynamics.
The Advection-DiffusionModels enables the fine spatial-temporal resolution of species
concentration and provide valuable insights into the phenomenology of species interac-
tion in our system. We found them to be useful tools for understanding the evolution
of aggregated parameters μ1, μ2, δ predicted by our simulations. More specifically, by
means of the Advection-DiffusionModels we were able to identify a number of important
regimes of toxin penetration that may have significant implications for the assessment for
the antibody protection properties.
These regimes can be best described by using the ‘transport phenomena’ terminol-
ogy which is well-established in chemical engineering, for instance see [22,23]. Initially
all species are concentrated in spherical layers between the external sphere, cell mem-
brane, and ER envelope (i.e. (ρm, ρe) and (ρn, ρm)). This layer structure results in strong
radial gradient of toxin concentration which facilitates the development of diffusion fluxes
across the system (since cell membrane and ER envelope are ‘penetrable’). Without anti-
body toxin would eventually be flushed out of the systemwhen it reaches the ER envelope
driven by the pure diffusion mechanism. The advection velocity will change toxin trans-
port at one part of the system (from diffusion dominated to advection dominated). How
much toxin can be blocked by antibody during this transition to ER depends on a number
of factors. They include the initial reactants concentration (toxin and antibody), relative
value of toxin advection flux, and reaction time of toxin-antibody binding. It also depends
on the availability of antibody in the areas of high toxin concentration to maximize the
effective toxin-antibody binding. The last condition (local availability of antibody for
binding toxin) is determined by the antibody diffusivity and can be validated by inspection
of the solutions of Advection-Diffusion Models (spatial-temporal outputs). This valida-
tion enables justifiable comments on the relative reduction of toxin in the output of the
system (on ER envelope) and the specific values of antibody protection parameters μ1,
μ2. This approach was employed in our study to identify and investigate the most ‘vulner-
able’ regimes of toxin penetration and comment on the shapes of functions μ1(t), μ2(t).
Some of these regimes are presented in examples below.
Furthermore such a ‘chemical engendering’ approach provides a clear path for the sys-
tem optimization. Indeed, from the formal point of view our system (cell) can be cast as a
chemical reactor with the only output (product), being the toxin concentration at the ER
envelope. In this context, the aim of antibody treatment is to reduce this output by dis-
tributing the minimal amount of a given antibody across the system. We anticipate that
in such settings the optimization problem can be tacked in reduced parameter space by
using the established framework for chemical reactor design [23,24].
The results of the numerical solutions are presented in Figures 2, 3, 4, 5 and 6. Themain
purpose of our study was to estimate the effects of the toxin diffusivity, advective veloc-
ity, and the ‘ER interface’ parameter γ (rate constant of ER absorption) on the protective
properties of the antibody in both scenarios. As such, most plots illustrate the effect of
these parameters. In order to provide a consistent comparison of the simulation outputs
we apply the same initial concentration of antibody or the same initial amount (but differ-
ent concentration) of antibody. The equality of the initial amount leads to the following
relation for the initial concentration
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u0iA = ηu0eA , η =
(ρe/ρm)3 − 1
1 − (ρn/ρm)3 (18)
which follows from the simple geometrical arguments. All calculations were performed
for ρe = 0.18, ρm = 0.1, ρn = 0.02 for which η = 4.871. This condition becomes espe-
cially important for the comparison of full and reduced models. Unless stated otherwise
the value of all parameters (except depicted in plots) are assumed to be fixed and equal to
those given above.
As mentioned, our simulations reveal a number of interesting regimes of toxin prop-
agation. In particular, in Scenario I we observed that there was a range of parameters
(γ , κT , v) for which the diffusive flux of toxin, κT∂ρuT |ρ=ρm = (r0kθ − vuT )|ρ=ρm ,
becomes negative near the cell membrane, i.e., it is opposite to the advective flux directed
toward ER. This may reduce the total toxin flux inside the cell and providemore favorable
condition for toxin-antibody binding.





















Figure 2 Influence of toxin diffusivity and absorption constant on antibody protection factor.
(a) Scenario I. Solid and dashed lines correspond to value of uT determined for γ = 0.1 and γ = 0.05. Toxin
diffusivity κT : 10−2 (1), 10−3 (2), 5 · 10−4 (3). (b) Scenario II. Absorption constant γ = 0.1, toxin diffusivity κT :
10−2 (1), 5 · 10−4 (2). u0,eA = u0,iA = 1 in cases (a) and (b).
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Figure 3 Effect of variation of toxin diffusivity on parameter δ in case u0,eA = 1, u0,iA = 4.87. Solid and
dashed lines correspond to value of δ determined for γ = 0.1 and γ = 0.01. Toxin diffusivity κT : 10−2 (1),
10−3 (2), 5 · 10−4 (3).
In other words this phenomenon is a direct result of toxin transport being dominated by
directional advection (due to velocity v). In our simulations this regime occurred for slow
toxin transport characterized by parameters γ , κT , v and the slow forward reaction rate
for toxin-antibody binding. It is worth mentioning that the similar phenomenon has been
reported in toxicological studies [17]. We found that the development of this ‘advection








Figure 4 Long-time asymptotic behavior of metric parameter δ(t). Solid and dashed lines correspond to
δ determined for γ = 0.1 and γ = 0.01 in case u0,eA = u0,iA = 1, κT = 0.01.
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Figure 5 Effect of variation of toxin diffusivity and absorption constant on parameter δ. Toxin
diffusivity: (a) κT = 10−4, (b) κT = 10−3. Solid (u0,eA = u0,iA = 1) and dashed (u0,eA = 1, u0,iA = 4.87) lines
correspond to δ determined by advection-diffusion models, and bullets (u0,eA = u0,iA = 1) and circles (u0,eA = 1,
u0,iA = 4.87) to δ determined by well-mixed models for γ : 0.1 (1), 0.01 (2).
dominated’ region of toxin transport with reverse diffusive flux has a positive effect on
antibody protection properties since it effectively increases the efficiency toxin-antibody
binding (by increasing time available for toxin-antibody reaction).We also solved problem
(2)–(9) using position-dependent advective velocity v(ρ) which is zero at the membrane
and then rapidly tends to a constant value as ρ → ρn. In this case because of the boundary
condition (4)2, the diffusive toxin flux near the cell membrane is directed to ER.
Figure 2a illustrates solution for antibody protection factor for different values of toxin
diffusivity κT and the ER absorption rate γ (with all other parameters being fixed). These
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Figure 6 Effect of variation of toxin advection velocity v on parameter δ. Advection-diffusion models
(solid lines): v = 0.001, γ = 0.01 (1), v = 0.001, γ = 0.1 (2), v = 0.05, γ = 0.01 (3), v = 0.05, γ = 0.1 (4); toxin
diffusivity: (a) κT = 10−3, (b) κT = 10−4. Well-mixed models (dashed lines): γ = 0.01 (1), γ = 0.1 (2).
results demonstrate the general trend of δ(t) increase with the increase of κT and γ . For
function μ1(t) (Scenario I, Eq. (7)) we found noticeable non-monotonic behavior for all
κT and γ . This implies that there is a time interval for which the protection potential of
antibody in Scenario I reaches its maximum and then decays. According to Figure 2a this
time interval is of order of 500 s.
Figure 2b demonstrates the evolution of antibody protection factor μ2(t) (Scenario II,
Eq. (15)) for a range of parameters κT and γ . Although the shape of function μ2 is very
different (it is always monotonically decreasing) we can conclude that the value of μ2
drops twice during the first time interval (about 500 s). Simulations for γ = 0.1, 0.05
and κT = 10−2, 10−3, 10−4 provide almost identical outputs. This leads to an important
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conclusion of insignificance of parameters κT and γ for the prediction of antibody pro-
tection factors in Scenario II which is a direct consequence of equation decoupling for
extracellular and intracellular domain discussed above.
The plots in Figure 3 illustrate the effect of variation of parameters κT and γ on the
comparative protective skills of the same antibody. This effect is described in terms of
metric factor δ(t), Eq. (1). Our simulations generally demonstrate the decrease of param-
eter δ(t) as γ or κT decrease. The simulations have been performed for the same initial
amount of antibody (Eq. (18)) as well as for the same initial concentration (results not pre-
sented here). We observe that depending on value of κT and γ there exists a time interval
in which δ(t) < 1, i.e. the application of the antibody in Scenario I is more efficient than
in Scenario II. We found that this interval grows as κT or γ decreases. Overall we found
that the condition δ(t) < 1 is rather sensitive to the ER absorption rate γ . This conclusion
is intuitively clear since by reducing value of γ we also reduce the toxin flux through the
system facilitating more effective antibody-toxin binding which, in turn, leads to more
favorable output for Scenario I.
Figure 4 demonstrates some universal behaviors of function δ(t) that we identified for a
broad range parameters of our study. Our simulations reveal that for some intermediate
time (t ∈ (2 · 104; 106) seconds) function δ(t) may approximately saturates to a constant
plateau (depending on values of γ and κ), before it rapidly decays to zero. This is illus-
trated by two plots presented in Figure 4 (note different time scales). In particular we
found that for u0iA = u0eA , γ = 10−1, κT = 10−2 function δ(t) varies very insignificantly
(less that 10%, between 4.9 and 5.2) for the time interval (t ∈ [2 ·104; 5 ·105]) seconds, then
it decreases and vanishes as t → ∞. Note, the limit δ(t) → 0 occurs at the unpractically
long times, so it has more methodologically interest. We do not have a clear explanation
of the specific numerical value of this saturation limit (δ(t) ≈ 5); this will require further
investigation.
Figure 5 shows the comparative results of the performance of the full Advection-
Diffusion models (ADM1, ADM2) and the reduced models (WM1, WM2). We compare
estimations of the metric parameter δ(t) provided by these models for different toxin
diffusivity κT , ER absorbtion rate γ , and initial antibody concentration. We found that
for the high toxin diffusivity (κT ≥ 10−2) the outputs of full model and reduced mod-
els are almost identical. The differences between the estimations of δ(t) increases as κT
decreases and for κT < 10−4 the reduced models fails to provide any meaningful predic-
tions (Figure 5b). We found that even for κT > 10−4 the reduced models usually poorly
handle the non-monotonic behavior of function δ(t) at short times. At the long times we
observed that for the broad range of parameters the full and reduced models are reason-
ably aligned and can yield reasonable estimation of δ as t → ∞ (within 20% accuracy),
Figure 5a.
The plots in Figure 6 illustrate the effect of the toxin advective velocity, v, on the
prediction of the protection factor δ(t), Eq. (1). Two different values of toxin advec-
tive velocity are used for simulations, v = 10−3 and v = 5 · 10−4 with γ = 0.1. The
toxin diffusivity was κT = 10−3 (Figure 6a) and 10−4 (Figure 6b) and the same val-
ues of the initial antibody concentration in both scenarios were used. Only two plots in
these figures correspond to the well-mixed models, since they do not involve advective
velocity v. In general we observed the growth of δ(t) as advective velocity increases, so
Scenario II becomes more favorable. This is intuitively clear because with an increase of
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v the toxin neutralization time decreases and therefore Scenario I becomes less favor-
able. We also noticed the improved accuracy of reduced models as v increased. So, for
given κT and γ , the difference between δ(t) determined by Advection-Diffusion mod-
els and Well-Mixed ones is small only if advective velocity, v, is small. But, for small γ ,
it dramatically increases as v grows, while for large γ it increases but not so dramati-
cally. This is due to the switching to the advection dominated transport of toxin in the
system.
Conclusions
We present a new modeling framework to evaluate the protective potential of various
antibodies. This framework is based on the equation for the diffusion- and advection-
diffusion transport of all species in the extracellular and intracellular domains and
include mass-action kinetics for toxin, receptor and antibody. The advection term and
radiation boundary condition on the Endoplasmic Reticulum envelope were used to
model the toxin transport via the microtubule network. We estimated the protection
factor of antibody (relative reduction of toxin concentration near the ER) for two sce-
narios of operational relevance, viz., when the antibody is delivered externally to the
cell and when it is delivered directly into the cytosol. To provide a consistent com-
parison of antibody performance we estimated the evolution of the metric factor δ(t),
which is defined as the ratio of the protections factors of an antibody for each sce-
narios. Based on this definition the condition δ(t) < 1 over a time span implies
that the internally introduced antibody has better protective capability during this time
while in the opposite case (δ(t) > 1) the internalized antibody is more effective. In
this study simulated both cases. Our models reveal that depending on values of some
parameters (primary toxin diffusivity and ER absorbtion rate) the plot of function δ(t)
can significantly change its shape while keeping the same short- and long-time limits,
by undergoing a saturation stage at the intermediate times with a universal value of
δ ≈ 5.
To reduce the computational burden of the Advection-Diffusion Model (a system of
nonlinear PDEs) we investigated its possible simplification. By employing the well-mixed
assumption we reduced the Advection-Diffusion Model to the compartment or rate
model (set of ODEs)which can be easily solvedwith any numerical solver. For an extended
range of parameters we found that predictions of the compartment model can provide
about±20% accuracy in estimation of antibody protection potential (depending on values
of some other parameters), but with decreasing toxin diffusivity limit the compartment
model become a poor predictor and should not be used in this context. This finding can
provide some appreciation of a possible trade-off between simplification and fidelity in
toxicological modelling and can be an important criterion for selection of operational
models.
We would like to emphasise that the comparative study reported in the present paper
can be treated only as the first step for the application of the proposed modelling
framework to the practical pharmacological studies. More extensive simulations (to pro-
vide statistically viable outcomes), data fitting and an established strategy for parameter
optimization using toxicological observations will be necessary.
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